Literature DB >> 9826581

Role of 4-1BB in immune responses.

D S Vinay1, B S Kwon.   

Abstract

4-1BB is an inducible T cell surface receptor which belongs to the tumor necrosis factor receptor superfamily, a group of cysteine-rich cell-surface molecules. Both human and mouse 4-1BB recently received HLDA nomenclature. Naive T cells lack 4-1BB, which is not only induced upon T cell activation, but also remains on activated T cells. The natural ligand for 4-1BB, 4-1BBL is also induced and is found on activated antigen-presenting cells. Cross-linking of the 4-1BB molecule by agonistic antibody transmits a distinct and potent co-stimulatory signal leading to the activation and differentiation of CD4(+) and CD8(+) cells. 4-1BB transmits signals through the TRAF2-NIK pathway and activates NF-kappaB. Signals relayed through 4-1BB inhibit activation-induced cell death and rescue the immune system during the post-CD28 phase. Antibodies to the 4-1BB molecule can increase GVHD, accelerate the rejection of cardiac allograft and skin transplants, and eradicate established tumors. Interference with the 4-1BB-4-1BBL pathway may be of therapeutic use in the treatment of HIV infection. 4-1BB-deficient mice show dysregulated immune responses and mount elevated Ig responses to T-dependent antigens. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826581     DOI: 10.1006/smim.1998.0157

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  78 in total

1.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens.

Authors:  A Jeurissen; J L Ceuppens; X Bossuyt
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

3.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

Review 4.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

5.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

Review 6.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

7.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

8.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.

Authors:  Aruna Bitra; Tzanko Doukov; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

9.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

10.  4-1BB functions as a survival factor in dendritic cells.

Authors:  Beom K Choi; Young H Kim; Patrick M Kwon; Sang C Lee; Sang W Kang; Moon S Kim; Myoung J Lee; Byoung S Kwon
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.